News >

Dabrafenib Plus Trametinib Demonstrates Activity in GI Cancers

Brandon Scalea
Published: Saturday, Nov 17, 2018

Zev A. Wainberg

Zev A. Wainberg, MD
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) led to encouraging responses in patients with rare, incurable cancer of the digestive tract, according to phase II data presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.1

 

References

  1. Wainberg ZA. Patients with rare, incurable digestive tract cancers respond to new drug combination. In: Proceedings from the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; November 13-16, 2018; Dublin, Ireland. Abstract 2. https://bit.ly/2Px5aGf.
  2. Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma [published online ahead of print October 22, 2018]. J Clin Oncol. doi: 10.1200/JCO.18.01219.
  3. Planchard D, Smit EF, Groen HMJ, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4.
  4. Subbiah V, Kreitman RJ, Wainberg AZ, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7-13. doi: 10.1200/JCO.2017.73.6785.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x